IP Library Granted Patent US 8,871,996
Granted Patent B2
US 8,871,996 · App. 13/155,491 · Granted Oct 28, 2014

Mice expressing human voltage-gated sodium channels

Inventors: Lynn Macdonald (White Plains, NY); Andrew J. Murphy (Croton-on-Hudson, NY); Michael L. LaCroix-Fralish (Sleepy Hollow, NY); Nicole M. Alessandri Haber (Rye, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
A01K67/0278A01K2267/0356A01K2217/072A01K2227/105
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,871,996
App. No.
13/155,491
Granted
Oct 28, 2014
Kind
B2
Abstract

Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a humanization of an extracellular loop of an endogenous Na V channel gene, in particular a humanization of the one or more extracellular pore loops of a Na V 1.7 channel protein. Genetically modified non-human animals are also provided, wherein the genetic modification comprises replacement of an endogenous Na V channel gene, in particular a replacement of the endogenous Na V 1.7 gene with a human Na V 1.7 gene, and wherein the genetically modified non-human animals are capable of generating action potentials and communicating through the excitable cells of the genetically modified non-human animals via the expressed human or humanized Na V 1.7 protein the surface of the excitable cells. Genetically modified mice are described, including mice that express the human or humanized Na V 1.7 gene from the endogenous Na V 1.7 locus, and wherein the mice comprise functional β-subunits.

Claims (34)

1. A genetically modified mouse whose genome comprises:

a Na V 1.7 α-subunit gene that is chimeric in that it includes both human and mouse sequences, wherein the human sequence comprises a nucleotide sequence encoding an extracellular pore loop of a domain of a human Na V 1.7 α-subunit selected from a DI/S5-S6 and DIII/S5-S6 loop, and the mouse sequence comprises a nucleotide sequence encoding at least transmembrane segments of a mouse Na V 1.7 α-subunit, wherein the Na V 1.7 α-subunit gene is operably linked to a Na V 1.7 promoter.

2. The genetically modified mouse of claim 1 , wherein the Na V 1.7 promoter is a mouse Na V 1.7 promoter.

3. The genetically modified mouse of claim 1 , wherein the Na V 1.7 promoter is a human Na V 1.7 promoter.

4. The genetically modified mouse of claim 1 , wherein the extracellular pore loop is DI/S5-S6.

5. The genetically modified mouse of claim 1 , wherein the extracellular pore loop is DIII/S5-S6.

6. A genetically modified mouse whose genome comprises:

a Na V 1.7 α-subunit gene that is chimeric in that it includes both human and mouse sequences, wherein the human sequence consists of exons 2-28 of a human Na V 1.7 α-subunit gene encoding a human Na V 1.7 α-subunit, the mouse sequence comprises exon 1 of a mouse Na V 1.7 α-subunit operably linked to a Na V 1.7 promoter, and the mouse sequence comprising exon 1 is upstream and linked contiguously to the human sequence consisting of exons 2-28 of a human Na V 1.7 α-subunit gene encoding a human Na V 1.7 α-subunit.

7. The genetically modified mouse of claim 6 , wherein the Na V 1.7 promoter is a human Na V 1.7 promoter.

8. The genetically modified mouse of claim 6 , wherein the Na V 1.7 promoter is a mouse Na V 1.7 promoter.

9. The genetically modified mouse of claim 6 , wherein the mouse does not detectably express an endogenous Na V 1.7 α-subunit.

10. A cell or tissue derived from the mouse according to any one of claims 4 , 5 and 6 .

11. A genetically modified mouse according to any one of claims 4 , 5 and 6 , wherein the nucleotide sequence encoding a chimeric or full-length human Na V 1.7 α-subunit comprises a substitution associated with a human pain disorder.

12. The genetically modified mouse of claim 11 , wherein the human pain disorder is select from erythromelalgia (IEM), paroxysmal extreme pain disorder (PEPD) and congenital indifference to pain (CIP).

13. A method of making a genetically modified mouse that expresses a Na V 1.7 α-subunit protein from an altered endogenous Na V 1.7 α-subunit locus, the method comprising:

(a) targeting an endogenous Na V 1.7 α-subunit gene in a mouse ES cell with a nucleic acid construct comprising a chimeric Na V 1.7 α-subunit gene that is operably linked to a Na V 1.7 promoter and includes both human and mouse sequences,

wherein the chimeric Na V 1.7 α-subunit gene comprises a human sequence comprising a nucleotide sequence encoding an extracellular pore loop of a domain of a human Na V 1.7 α-subunit selected from a DI/S5-S6 and DIII/S5-S6 loop and a mouse sequence comprising a nucleotide sequence encoding at least transmembrane segments of a mouse Na V 1.7 α-subunit, or

wherein the chimeric Na V 1.7 α-subunit gene comprises a mouse sequence comprising exon 1 of a mouse Na V 1.7 α-subunit upstream and linked contiguously to a human sequence consisting of exons 2-28 of a human Na V 1.7 α-subunit gene;

(b) obtaining a modified mouse ES cell comprising an endogenous Na V 1.7 α-subunit gene that is chimeric and includes the human and mouse sequences of (a); and,

(c) creating a genetically modified mouse using the modified ES cell of (b).

14. The method of claim 13 , wherein the human sequence is exons 2 to 28 of a human Na V 1.7 α-subunit gene.

15. The method of claim 13 , wherein the human sequence is exons 7 to 9 of a human Na V 1.7 α-subunit gene.

16. The method of claim 13 , wherein the human sequence is exons 23 to 25 of a human Na V 1.7 α-subunit gene.

17. A method for generating an immortalized dorsal root ganglion (DRG) neuronal cell line, comprising:

(a) isolating a DRG cell from the mouse according to any one of claims 4 , 5 and 6 ;

(b) introducing into the DRG cell of (a) a vector that encodes an oncogene and a selectable marker;

(c) selecting a cell containing the vector of (b);

(d) maintaining the cell of (c) in culture thereby generating an immortalized DRG neuronal cell line.

18. The method of claim 17 , wherein the vector is a retroviral vector.

19. The method of claim 17 , wherein the oncogene is selected from c-Sis, a receptor tyrosine kinase, a cytoplasmic tyrosine kinase, Raf, a regulatory GTPase, and Myc.

20. The cell or tissue of claim 10 , wherein the cell or tissue detectably expresses a human Na V 1.7 α-subunit.

21. The cell or tissue of claim 10 , wherein the cell or tissue does not detectably express a mouse Na V 1.7 α-subunit.

22. The cell or tissue of claim 21 , wherein the cell is a neuronal cell and the human Na V 1.7 α-subunit is detectably expressed on the cell surface.

23. The cell or tissue of claim 22 , wherein the neuronal cell is a DRG neuron.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2011
From: MACDONALD, LYNN; MURPHY, ANDREW J.; LACROIX-FRALISH, MICHAEL L.; ALESSANDRI HABER, NICOLE M.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 027243/0259 →
Continuity (3)
Provisional Application 61485488 · May 12, 2011
Provisional Application 61352920 · Jun 9, 2010
Related Publication 20110307966A1 · Dec 15, 2011